Need a business?

Fill out the form for our tailored recommendations, and we'll get in touch with you shortly.
About Us
Guangzhou Vbio Pharma Co., Ltd.

Founded in 2015, Guangzhou Vbio Pharma Co., Ltd. (hereinafter referred to as "VBIO") is a certified high-tech enterprise and a global leader in reproductive biologics for human and animal health, with expertise in in vitro fertilization (IVF) and fertility solutions.

Supported by leading experts in protein biologics with professional and academic backgrounds at MSD, Yale University, the University of California, Berkeley, the University of Washington, and the University of Toronto, VBIO has a team of over 200 professionals specializing in the research, development, manufacturing, and commercialization of active pharmaceutical ingredients (APIs), pharmaceutical formulations, veterinary medicines, intimate health products, and personal care products.

With a registered capital of RMB 65 million and operations based in the Guangzhou Economic and Technological Development Zone, VBIO is committed to delivering world-class innovation and high-quality solutions to customers worldwide.

Learn more
about1
R&D Expert Team
Recruited more than
200+
members
about2
Registered Capital
Reaching an amount of
65+
million RMB
about3
Patents
Possessing more than
50+
pieces
材料-(1)
Patents
Serving over
30000000
pigs, cattle and sheep
材料
Factory Area
Covering a space of
100000
㎡
Research&OEM

We are committed to providing our customers with innovative, safe, and high-quality pharmaceutical products and customized OEM solutions.

极简蓝色点阵网格背景
201801121831103110
VFG600

Long‑acting Recombinant Follitropin Compound Preparation. It significantly improves the oestrus and mating rate as well as the overall conception rate of sows, shortens non‑productive days, and its performance meets or exceeds that of comparable imported products.

201801121832323232
UN015

Class‑I New Veterinary Drug, a recombinant protein produced by genetic engineering and mammalian cell expression. It is applied for estrus induction and batch production management in sows. It features stable quality, high safety, with potency complying with the standards of European Pharmacopoeia.

201801121831513151
UN003
Class‑I New Drug. A recombinant protein produced by genetic engineering and mammalian cell expression. It is applied for oestrus induction and ovulation induction in female livestock, and ovulation promotion in artificial propagation of aquatic animals. It features stable quality and high safety, with potency over 5 times the current domestic standard.
201801121832103210
UNO08
Class‑I New Drug, globally innovative recombinant protein drug manufactured via genetic engineering and mammalian cell expression. It is used for oestrus induction and batch production management in sows, as well as superovulation in cattle and sheep. It boasts a long half‑life, stable quality and high safety.
0929-1
Re-GnRH-leukotoxin
Recombinant GnRH-leukotoxin fusion protein
0929-2
WJT202
Recombinant porcine IL-29 (interferon-λ1) fusion protein for protection against PEDV and PRRSV
0929-3
VJT305
Canine IL-31 antibody (for atopic dermatitis; benchmarked against Cytopoint)
0929-4
WJT311

Anti-NGF antibody (for osteoarthritis pain; benchmarked against Librela)

Product

All products available as API raw materials or finished formulations. Custom specifications and packaging supported. Veterinary products support OEM/ODM services.

Pregnant Mare Serum Gonadotropin
Pregnant Mare Serum Gonadotropin
Female animals induce estrus and promote follicular development, as well as superovulation during embryo transfer.
Chorionic-Gonadotropin-(Animal)
Human Chorionic Gonadotropin
ART/IVF trigger ovulation, luteal support; Male hypogonadism
白底极简 TB-500 玻璃药瓶
TB-500
白底居中的 BPC-157 透明药瓶
BPC-157
极简透明玻璃替尔泊肽药瓶
Tirzepatide
极简医药西林瓶产品照
Cagrilintide
瑞他鲁肽粉末药瓶展示
Retatrutide
威一配V-OneMate™
V-OneMate™
The first one-time breeding technology
优蕴康V-Follimate®
V-Follimate®
Estrus synchronization & batch production
威乐萌V-Romone®0
V-Romone®
Cat calming & stress relief
6a4dedacfb15482d7a47f4740d6c804
Male Delay Spray
Short-term/Long-term delay
afa3cc486adf295ef4d489e08a6f508
Personal Lubricant
Personal lubrication
Learn more
Application scenarios
VBIO PHARMA Experts in reproduction
3-1
Conference Information | Gather at Leman · New Power in Insemination, Co‑create Innovative Breeding
The 13th Leman China Swine Conference was grandly held in Chengdu, Sichuan from October 25 to 27, 2024. Guangzhou Weisheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Weisheng”) hosted a pre‑conference technical seminar themed “New Power in Insemination, Co‑create Innovative Breeding” on October 24. During the three‑day exhibition from October 25 to 27, Weisheng’s booth welcomed numerous guests and peers. Core competitive products including V‑One‑Mate® and the new product Weiyunbao® drew wide attention for visits and technical exchanges from livestock industry participants.​
新闻3
V‑OneMate® Group Application Case | Boost Production Performance for Batch‑mode Implementation
Batch sow production represents a vital management transformation and an inevitable trend in modern intensive farming. It delivers remarkable long‑term benefits, including higher production efficiency, improved biosecurity and balanced output. Nevertheless, the transition from continuous production to batch production may bring temporary setbacks in key performance indicators such as conception rate and farrowing rate, discouraging some pig farms from making the shift. These challenges can be effectively mitigated through well‑planned batch‑production roll‑out, precise hormone‑based technical application and standardized staff operation management. Such measures help pig farms enhance production performance and achieve a smooth transition during transformation, so as to secure improved economic returns and capture the long‑term dividends brought by batch production.​
新闻
Invitation | VBIO Pharma Invites You to Attend the 16th China Dairy Industry Conference in Xiamen
The 16th China Dairy Industry Conference and 2025 China Dairy Industry Exhibition will grandly open at Xiamen International Conference & Exhibition Center from July 13 to 15, 2025.​
5-1
Gilt Special Topic | V‑OneMate® Achieves a 22.6% Increase in Breeding Conception Rate of Sows under the 21‑day Batch Production Model (South China)
Since the launch of V‑OneMate®, its clinical efficacy has been validated by multi‑round data accumulated from multiple Top30 group‑owned pig farms and large‑scale commercial farms. The product solution can significantly improve the breeding conception rate of sows with statistically‑significant differences. To further expand and accumulate field application cases of V‑OneMate® in large‑scale pig farms, this article presents its performance among gilts at a large‑scale pig farm in South China. The results show that V‑OneMate® delivered a notable improvement in the breeding conception rate of gilts, rising from 65.5% to 88.1%, representing a 22.6% increase. Meanwhile, it reduces reliance on estrus‑detection skills, as well as mating frequency and semen consumption.​
Cooperative Clients

We are committed to providing our customers with innovative, safe, and high-quality pharmaceutical products and customized OEM solutions.

Overseas
Overseas
China
China
Guangzhou Vbio-pharma
Co.,Ltd
Contact Number
Business Cooperation:+86-16624628010
Reception:+86-16624628010
CompanyAddress
No. 9 Dongcheng 1st Street, Guangzhou Economic & Technological Development Zone, Guangzhou,China


Mail: mindy@vbio-pharma.com
Code：510730
Links
Guangzhou Youhuikang Biological Technology Co.,Ltd. South China Agricultural University
Copyright © VBIO Pharma All Rights Reserved.